Names Under Consideration
USAN Council's statement on the use of USAN as domain names:
A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.
The following list of names for the drugs described are "under consideration" by the USAN Council:
July-September 2009
acomitinib: treatment of cancer
anilutamide: treatment of cancer
avalsulfatase-alfa: treatment of metachromatic leukodystrophy
azfibrocel-T: treatment of nasolabial fold wrinkles
cenicriviroc: treatment of HIV
crizotinib: treatment of cancer
fosdevirine: treatment of HIV
ganacitumab: treatment of cancer
gesvokinzumab: treatment of diabetes
girentuximab: treatment of cancer
ioflubenzamide I 131: diagnostic agent
lucagepant: treatment of migraine
maraciclatide: imaging agent
minenesib: treatment of cancer
pralenesib: treatment of cancer
nesituximab: treatment of cancer
ozantinib: treatment of cancer
peginesatide: treatment of anemia
pegsitacase: treatment of gout
reltipostat: treatment of disorders characterized by hyperserotonemia
remestemcel-L: cell therapy
rosponezumab: treatment of Alzheimer's disease
samalizumab: treatment of cancer
sotacitinib: treatment of inflammatory disorders
taprenepag: treatment of glaucoma or ocular hypertension
tegapepimut-R: therapeutic cancer vaccine
telaxaban: anticoagulation
trastuzumab emtansine: treatment of cancer
uridine triacetate: antidote for 5 fluorouracil overdose toxicity
vipadenant: treatment of Parkinson's disease
Any comments or protests should be addressed to Stephanie Shubat, USAN Program Director, American Medical Association, 515 North State Street, Chicago, IL 60654, or sent via e-mail to USAN@ama-assn.org.
